aslan004
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2018 (NCT03721263)
Timeline
Indications
Mechanism of action
- Interleukin 13 receptorINHIBITOR
Interleukin 13 receptor inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05694884 | Phase 2 | Dec 21, 2022 | Aslan Pharmaceuticals |
| NCT05158023 | Phase 2 | Dec 31, 2021 | Aslan Pharmaceuticals |
| NCT04090229 | Phase 1 | Sep 30, 2019 | Aslan Pharmaceuticals |
| NCT03721263 | Phase 1 | Oct 15, 2018 | Aslan Pharmaceuticals, IQVIA |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aslan Pharmaceuticals | For profit | 4 | 4 | 2 | 2018 |
| IQVIA | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1